Bone Biologics is pursuing a better and more effective way of dealing with back pain requiring surgery by developing bone regeneration in spinal fusion using the recombinant human protein known as NELL-1/DBX, or NB1. The company released its 3Q2024 financial results that showed good cash, low debt and good cost controls. Recently, the company also announced the first human patients have been treated with NB1, marking an important milestone for BBLG.
